p53 expression and prognosis in gastric carcinoma

Abnormalities of the p53 gene have been identified in many malignancies, with reports of aberration in over half of colorectal, lung, breast and hepatocellular carcinoma cases. The normal gene acts as a recessive oncogene, while mutations change the apparent function to that of a dominant oncogene....

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 50; no. 6; p. 859
Main Authors Martin, H M, Filipe, M I, Morris, R W, Lane, D P, Silvestre, F
Format Journal Article
LanguageEnglish
Published United States 01.04.1992
Subjects
Biomarkers, Tumor - analysis
Genes, p53
Humans
Immunoenzyme Techniques
Life Tables
Prognosis
Stomach Neoplasms - genetics
Stomach Neoplasms - pathology
Stomach Neoplasms - surgery
Time Factors
Tumor Suppressor Protein p53 - analysis
Online AccessGet more information

Cover

More Information
Summary:Abnormalities of the p53 gene have been identified in many malignancies, with reports of aberration in over half of colorectal, lung, breast and hepatocellular carcinoma cases. The normal gene acts as a recessive oncogene, while mutations change the apparent function to that of a dominant oncogene. In this investigation a 3-layered immunoperoxidase technique was applied to routinely fixed and paraffin-embedded tissue sections from 125 gastric carcinomas, using a polyclonal anti-p53 antibody (CM-I). We found that 57% of these carcinomas expressed high levels of p53 protein (positive nuclear staining). Survival analysis revealed a strong association between p53 status of the tumour and patient survival time after diagnosis (p = 0.02, Mantel-Cox Test); odds ratio of death, 2.09 (95% confidence interval 1.02 to 4.25). The 5-year survival of patients with p53-expressing tumours was 24%, compared with 56% for those non-p53-expressing tumours (the median survival times were 13 and 102 months, respectively).
ISSN:0020-7136
DOI:10.1002/ijc.2910500604